Cintel
News, events, congress coverage, analyst commentary, and historical sales in one landscape view.
For global bio-pharmaceutical companies
Commercial insight, from first signal to in-market brand.
PharmSight joins technology, business, and therapy-area expertise so teams can improve commercial performance and see the market clearly.
Gurugram · Boston · Zug
- 01
Technology
From Excel models to AI, dashboards, and automation built for pharma teams.
- 02
Business
Sales, marketing, access, and commercial operations treated as one system.
- 03
Pharma
Therapy depth across oncology, neurology, immunology, and beyond.
- 04
Partnership
100% client retention across 500+ projects delivered since 2018.
End to end
Support across the product lifecycle
Choose a stage. Each one draws on a different mix of PharmSight’s five practices.
In development
Forecasting and competitive intelligence while the asset is still in the pipeline.
- Market Sizing (Epi-based)
- Stage-Gate Assessments
- Asset Valuation Models
- Pipeline & Portfolio Monitoring
- Opportunity Assessment
At launch
Launch Excellence brings forecasting, landscape, and evidence into one plan.
- In-line & Pipeline Forecast
- Competitive Landscape
- Value Dossier Development
- Health Technology Assessment (HTA)
- Launch Excellence
In market
Analytics and access work once the brand is on the market.
- Sales Force Analytics
- Marketing Analytics
- Patient Analytics
- Access & Contracting Analytics
- Commercial Effectiveness
PharmSight in numbers
- 2018Founded
- 75+Skilled consultants
- 500+Projects delivered
- 100%Client retention
AI tool · Solution Finder
Find the right combination for your question.
Choose a therapy area, a goal, and a stage. The finder suggests the services and product PharmSight would usually combine. It is a guide written by the team, not a live model, and it does not use your data.
Oncology · Launch · In development
Launch Excellence, with a pipeline forecast
- In-line & Pipeline Forecast
- Market Sizing (Epi-based)
- Competitive Landscape
- Stage-Gate Assessments
Pair with Cintel for the landscape view.
Therapy area expertise
Depth where the science is hardest
Work spans large markets and specialised conditions, across the full development lifecycle.
Oncology
Commercial and evidence work across solid tumours and haematology.
- NSCLC
- Colorectal cancer
- Urothelial carcinoma
- Breast cancer
Neurology
Rare and high-burden neurological conditions, from pipeline to in-line brands.
- Multiple sclerosis
- Parkinson’s disease
- Epilepsy
- ALS
- Huntington’s disease
Immunology
Access, forecasting, and patient analytics for immune-mediated disease.
- Rheumatoid arthritis
- IBD and Crohn’s disease
- SLE
- Ankylosing spondylitis
Other markets
Broader therapy coverage beyond the three core areas.
- Diabetes and endocrinology
- Women’s health
- Nephrology
- Haemophilia
- Medical devices
Featured products
An AI toolkit that stays with the team
Conversity
AI role-play for negotiation and sales, including pricing and objection handling.
IntelliSight
Ask commercial data a question in plain language and see the chart beside the answer.
PharmLens
Part of the proprietary toolkit with Cintel and IntelliSight. A public product screen has not been released yet.
What clients say
The new brand strategy was supported by analysis done by PharmSight team.
News
Recent updates
Europe
European hub opens in Zug
PharmSight GmbH opens in Zug, with Conversity as part of the launch.
United States
A strategic hub in Boston
A US subsidiary closer to American brand and access teams.
Products
Four products, one line
Cintel, Conversity, IntelliSight, and PharmLens now sit together.
Contact
Tell us the decision in front of you.
Offices in Gurugram, Boston, and Zug. This form stays in your browser — nothing is sent.